ISB 1442 Trial for Relapsed Multiple Myeloma Terminated Early
A first-in-human Phase 1/2 trial of ISB 1442 in relapsed/refractory multiple myeloma was halted before completion.
Latest breakthroughs in cancer research, treatment, and prevention
643 articles
A first-in-human Phase 1/2 trial of ISB 1442 in relapsed/refractory multiple myeloma was halted before completion.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Cancer cells that downregulate SMC4 enter a low-proliferation, diapause-like state that resists standard chemotherapy, revealing a dangerous survival mechanism.
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
A 260-organoid biobank reveals statins target chemoresistant pancreatic cancer by disrupting cholesterol and glycosylation pathways.
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
A phase II trial tests ipilimumab and nivolumab paired with immunoembolization against liver-spread uveal melanoma.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
Researchers mapped distinct cell populations in human pancreatic ducts, finding two subtypes that drive aggressive, lower-survival pancreatic cancer.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.